세계의 제약용 아이솔레이터 시장 : 업계 동향과 예측(-2029년)

Global pharmaceutical isolator market is projected to register a CAGR of 14.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Global Pharmaceutical Isolator Market, By Type (aseptic isolators, containment isolators, bio isolators, sampling and weighing isolators, active pharmaceutical ingredient (API) manufacturing isolators, radiopharmaceutical isolators, production isolators, others), System Type (closed system, open system), Pressure (positive pressure, negative pressure), Configuration (floor standing, modular, mobile, compact, table top, portable, others), Application (sterility testing, manufacturing , sampling/ weighing/ distribution , medical device manufacturing, others), End User (hospitals, diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, others), Distribution Channel (direct tender, retail sales, third party distributors) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Global pharmaceutical isolator market are:

The growing demand for the pharmaceutical isolators across booming pharmaceutical

Low operational cost of Isolators

Market Players:

The key market players for Global pharmaceutical isolator market are listed below:

Getinge AG

Cytiva

AZBIL CORPORATION

CHIYODA CORPORATION

Hosokawa micron ltd

GERMFREE LABORATORIES, INC.

COMECER S.P.A.

LAF Technologies

Fedegari Autoclavi S.p.A.

TEMA SINERGIE S.P.A

GELMAN SINGAPORE PTE LTD

ITECO S.R.L.

HECHT TECHNOLOGIE GMBH

ISO TECH DESIGN

NUAIRE

SKAN AG

SCHEMATIC ENGINEERING INDUSTRIES

Bioquell ( Ecolab Solution)

M. BRAUN INERTGAS-SYSTEME GMBH

STERILINE S.R.L.

ENVAIR LIMITED

CHAMUNDA PHARMA MACHINERY PVT. LTD

Jacomex

ESCO PHARMA

TABLE OF CONTENTS

1 INTRODUCTION 37

• 1.1 OBJECTIVES OF THE STUDY 37
• 1.2 MARKET DEFINITION 37
• 1.3 OVERVIEW OF THE GLOBAL PHARMACEUTICAL ISOLATOR MARKET 38
• 1.4 CURRENCY AND PRICING 40
• 1.5 LIMITATIONS 40
• 1.6 MARKETS COVERED 40

2 MARKET SEGMENTATION 45

• 2.1 MARKETS COVERED 45
• 2.2 GEOGRAPHICAL SCOPE 46
• 2.3 YEARS CONSIDERED FOR THE STUDY 47
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
• 2.6 MULTIVARIATE MODELLING 52
• 2.7 MARKET APPLICATION COVERAGE GRID 53
• 2.8 SOURCE LIFELINE CURVE 54
• 2.9 DBMR MARKET POSITION GRID 55
• 2.10 VENDOR SHARE ANALYSIS 57
• 2.11 SECONDARY SOURCES 58
• 2.12 ASSUMPTIONS 58

3 EXECUTIVE SUMMARY 59

4 PREMIUM INSIGHT 63

• 4.1 PESTEL ANALYSIS 65
• 4.2 PORTER'S FIVE FORCES 66
• 4.3 INDUSTRIAL INSIGHTS: 67

5 GLOBAL PHARMACEUTICAL ISOLATORS MARKET: REGULATIONS 69

6 MARKET OVERVIEW 73

• 6.1 DRIVERS 75
  • 6.1.1 GROWING DEMAND FOR THE PHARMACEUTICAL ISOLATORS ACROSS BOOMING PHARMACEUTICAL 75
  • 6.1.2 LOW OPERATIONAL COST OF PHARMACEUTICAL ISOLATORS 75
  • 6.1.3 HIGH MAINTENANCE OF ASEPTIC CONDITIONS IN THE PRODUCTION OF PHARMACEUTICAL PRODUCTS 76
  • 6.1.4 LOW OPERATING COST OF PHARMACEUTICAL ISOLATORS & GROWING DEMAND IN THE BIOPHARMACEUTICAL INDUSTRY 76
• 6.2 RESTRAINTS 77
  • 6.2.1 STRINGENT GOVERNMENTAL REGULATIONS 77
  • 6.2.2 HIGH COST OF INSTALLATION & LIMITED ADOPTION OF RABS 77
• 6.3 OPPORTUNITIES 78
  • 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 78
  • 6.3.2 TECHNOLOGICAL ADVANCEMENTS IN PHARMACEUTICAL ISOLATORS 78
  • 6.3.3 HIGH STERILITY ASSURANCE 79
• 6.4 CHALLENGES 79
  • 6.4.1 LACK OF SKILLED EXPERTISE 79
  • 6.4.2 ENGINEERING CHALLENGES FACED WHILE DESIGNING THE PHARMACEUTICAL ISOLATORS 80

7 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY TYPE 81

• 7.1 OVERVIEW 82
• 7.2 ASEPTIC ISOLATOR 85
• 7.3 ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS 85
• 7.4 CONTAINMENT ISOLATORS 86
• 7.5 BIO ISOLATORS 86
• 7.6 SAMPLING AND WEIGHING ISOLATORS 87
• 7.7 RADIOPHARMACEUTICAL ISOLATORS 87
• 7.8 PRODUCTION ISOLATORS 88
• 7.9 OTHERS 88

8 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE 89

• 8.1 OVERVIEW 90
• 8.2 OPEN SYSTEM 93
• 8.3 CLOSED SYSTEM 93

9 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE 94

• 9.1 OVERVIEW 95
• 9.2 POSITIVE PRESSURE 98
• 9.3 NEGATIVE PRESSURE 98

10 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION 99

• 10.1 OVERVIEW 100
• 10.2 FLOOR STANDING 103
• 10.3 MODULAR 103
• 10.4 MOBILE 104
• 10.5 COMPACT 104
• 10.6 TABLE TOP 105
• 10.7 PORTABLE 105
• 10.8 OTHERS 106

11 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION 107

• 11.1 OVERVIEW 108
• 11.2 STERILITY TESTING 111
• 11.3 MANUFACTURING 111
• 11.4 SAMPLING/WEIGHING/DISTRIBUTION 112
• 11.5 MEDICAL DEVICE MANUFACTURING 112

12 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL 113

• 12.1 OVERVIEW 114
• 12.2 DIRECT TENDER 117
• 12.3 RETAIL SALES 117
• 12.4 THIRD PARTY DISTRIBUTORS 118

13 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY END USER 119

• 13.1 OVERVIEW 120
• 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 123
  • 13.2.1 STERILE FILTERING 123
  • 13.2.2 AMPULE FILLING 123
  • 13.2.3 SYRINGE FILLING 124
  • 13.2.4 SAMPLING 124
  • 13.2.5 SAMPLE TESTING 124
  • 13.2.6 STERILITY TESTING 124
  • 13.2.7 PACKAGING 124
  • 13.2.8 OTHERS 124
• 13.3 CONTRACT RESEARCH ORGANIZATION 124
  • 13.3.1 STERILE FILTERING 125
  • 13.3.2 AMPULE FILLING 125
  • 13.3.3 SYRINGE FILLING 125
  • 13.3.4 SAMPLING 125
  • 13.3.5 SAMPLE TESTING 125
  • 13.3.6 STERILITY TESTING 125
  • 13.3.7 PACKAGING 126
  • 13.3.8 OTHERS 126
• 13.4 ACADEMIC AND RESEARCH INSTITUTES 126
  • 13.4.1 STERILE FILTERING 127
  • 13.4.2 AMPULE FILLING 127
  • 13.4.3 SYRINGE FILLING 127
  • 13.4.4 SAMPLING 127
  • 13.4.5 SAMPLE TESTING 127
  • 13.4.6 STERILITY TESTING 127
  • 13.4.7 PACKAGING 127
  • 13.4.8 OTHERS 127
• 13.5 HOSPITALS 128
  • 13.5.1 STERILE FILTERING 128
  • 13.5.2 AMPULE FILLING 128
  • 13.5.3 SYRINGE FILLING 129
  • 13.5.4 SAMPLING 129
  • 13.5.5 SAMPLE TESTING 129
  • 13.5.6 STERILITY TESTING 129
  • 13.5.7 PACKAGING 129
  • 13.5.8 OTHERS 129
• 13.6 DIAGNOSTIC LABORATORIES 129
  • 13.6.1 STERILE FILTERING 130
  • 13.6.2 AMPULE FILLING 130
  • 13.6.3 SYRINGE FILLING 130
  • 13.6.4 SAMPLING 130
  • 13.6.5 SAMPLE TESTING 130
  • 13.6.6 STERILITY TESTING 130
  • 13.6.7 PACKAGING 130
  • 13.6.8 OTHERS 131
• 13.7 OTHERS 131

14 GLOBAL PHARMACEUTICAL ISOLATOR MARKET, BY REGION 132

• 14.1 OVERVIEW 133
• 14.2 NORTH AMERICA 139
  • 14.2.1 U.S. 148
  • 14.2.2 CANADA 153
  • 14.2.3 MEXICO 158
• 14.3 EUROPE 163
  • 14.3.1 GERMANY 173
  • 14.3.2 FRANCE 178
  • 14.3.3 U.K. 183
  • 14.3.4 ITALY 188
  • 14.3.5 RUSSIA 193
  • 14.3.6 SPAIN 198
  • 14.3.7 TURKEY 203
  • 14.3.8 NETHERLANDS 208
  • 14.3.9 SWITZERLAND 213
  • 14.3.10 BELGIUM 218
  • 14.3.11 REST OF EUROPE 223
• 14.4 ASIA-PACIFIC 224
  • 14.4.1 CHINA 233
  • 14.4.2 JAPAN 238
  • 14.4.3 SOUTH KOREA 243
  • 14.4.4 INDIA 248
  • 14.4.5 AUSTRALIA 253
  • 14.4.6 SINGAPORE 258
  • 14.4.7 THAILAND 263
  • 14.4.8 MALAYSIA 267
  • 14.4.9 INDONESIA 271
  • 14.4.10 PHILIPPINES 276
  • 14.4.11 REST OF ASIA-PACIFIC 281
• 14.5 SOUTH AMERICA 282
  • 14.5.1 BRAZIL 291
  • 14.5.2 ARGENTINA 296
  • 14.5.3 REST OF SOUTH AMERICA 301
• 14.6 MIDDLE EAST & AFRICA 302
  • 14.6.1 SOUTH AFRICA 311
  • 14.6.2 SAUDI ARABIA 316
  • 14.6.3 U.A.E 321
  • 14.6.4 EGYPT 326
  • 14.6.5 ISRAEL 331
  • 14.6.6 REST OF MIDDLE EAST AND AFRICA 336

15 GLOBAL PHARMACEUTICAL ISOLATORS MARKET: COMPANY LANDSCAPE 337

• 15.1 COMPANY SHARE ANALYSIS: GLOBAL 337
• 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 338
• 15.3 COMPANY SHARE ANALYSIS: EUROPE 339
• 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 340

16 SWOT ANALYSIS 341

17 COMPANY PROFILE 342

• 17.1 GETINGE AB 342
  • 17.1.1 COMPANY SNAPSHOT 342
  • 17.1.2 REVENUE ANALYSIS 342
  • 17.1.3 COMPANY SHARE ANALYSIS 343
  • 17.1.4 PRODUCT PORTFOLIO 343
  • 17.1.5 RECENT DEVELOPMENT 343
• 17.2 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION) 344
  • 17.2.1 COMPANY SNAPSHOT 344
  • 17.2.2 REVENUE ANALYSIS 344
  • 17.2.3 COMPANY SHARE ANALYSIS 345
  • 17.2.4 PRODUCT PORTFOLIO 345
  • 17.2.5 RECENT DEVELOPMENT 345
• 17.3 AZBIL CORPORATION 346
  • 17.3.1 COMPANY SNAPSHOT 346
  • 17.3.2 REVENUE ANALYSIS 346
  • 17.3.3 COMPANY SHARE ANALYSIS 347
  • 17.3.4 PRODUCT PORTFOLIO 347
  • 17.3.5 RECENT DEVELOPMENTS 347
• 17.4 CHIYODA CORPORATION 348
  • 17.4.1 COMPANY SNAPSHOT 348
  • 17.4.2 REVENUE ANALYSIS 348
  • 17.4.3 COMPANY SHARE ANALYSIS 349
  • 17.4.4 PRODUCT PORTFOLIO 349
  • 17.4.5 RECENT DEVELOPMENT 349
• 17.5 HOSOKAWA MICRON LTD 350
  • 17.5.1 COMPANY SNAPSHOT 350
  • 17.5.2 COMPANY SHARE ANALYSIS 350
  • 17.5.3 PRODUCT PORTFOLIO 351
  • 17.5.4 RECENT DEVELOPMENTS 351
• 17.6 BIOQUELL, AN ECOLAB SOLUTION (A SUBSIDIARY OF ECOLAB) 352
  • 17.6.1 COMPANY SNAPSHOT 352
  • 17.6.2 REVENUE ANALYSIS 352
  • 17.6.3 PRODUCT PORTFOLIO 353
  • 17.6.4 RECENT DEVELOPMENT 353
• 17.7 CHAMUNDA PHARMA MACHNIERY 354
  • 17.7.1 COMPANY SNAPSHOT 354
  • 17.7.2 PRODUCT PORTFOLIO 354
  • 17.7.3 RECENT DEVELOPMENTS 354
• 17.8 COMECER S.P.A. (A SUBSIDIARY OF ATS AUTOMATION TOOLS) (2021) 355
  • 17.8.1 COMPANY SNAPSHOT 355
  • 17.8.2 REVENUE ANALYSIS 355
  • 17.8.3 PRODUCT PORTFOLIO 356
  • 17.8.4 RECENT DEVELOPMENT 358
• 17.9 ENVAIR TECHNOLOGY 359
  • 17.9.1 COMPANY SNAPSHOT 359
  • 17.9.2 PRODUCT PORTFOLIO 359
  • 17.9.3 RECENT DEVELOPMENTS 359
• 17.10 ESCO MICRO PTE. LTD 360
  • 17.10.1 COMPANY SNAPSHOT 360
  • 17.10.2 PRODUCT PORTFOLIO 360
  • 17.10.3 RECENT DEVELOPMENT 361
• 17.11 FEDEGARI AUTOCLAVI S.P.A 363
  • 17.11.1 COMPANY SNAPSHOT 363
  • 17.11.2 PRODUCT PORTFOLIO 363
  • 17.11.3 RECENT DEVELOPMENTS 363
• 17.12 GERMFREE LABORATORIES, INC. 364
  • 17.12.1 COMPANY SNAPSHOT 364
  • 17.12.2 PRODUCT PORTFOLIO 364
  • 17.12.3 RECENT DEVELOPMENT 366
• 17.13 GELMAN SINGAPORE 367
  • 17.13.1 COMPANY SNAPSHOT 367
  • 17.13.2 PRODUCT PORTFOLIO 367
  • 17.13.3 RECENT DEVELOPMENTS 368
• 17.14 HECT TECHNOLOGIE GMBH (2021) 369
  • 17.14.1 COMPANY SNAPSHOT 369
  • 17.14.2 PRODUCT PORTFOLIO 369
  • 17.14.3 RECENT DEVELOPMENT 369
• 17.15 ISO TECH DESIGN 370
  • 17.15.1 COMPANY SNAPSHOT 370
  • 17.15.2 PRODUCT PORTFOLIO 370
  • 17.15.3 RECENT DEVELOPMENTS 370
• 17.16 ITECO SRL 371
  • 17.16.1 COMPANY SNAPSHOT 371
  • 17.16.2 PRODUCT PORTFOLIO 371
  • 17.16.3 RECENT DEVELOPMENT 371
• 17.17 JACOMEX 372
  • 17.17.1 COMPANY SNAPSHOT 372
  • 17.17.2 PRODUCT PORTFOLIO 372
  • 17.17.3 RECENT DEVELOPMENT 372
• 17.18 LAF TECHNOLOGIES 373
  • 17.18.1 COMPANY SNAPSHOT 373
  • 17.18.2 PRODUCT PORTFOLIO 373
  • 17.18.3 RECENT DEVELOPMENTS 373
• 17.19 MBRAUN.(2021) 374
  • 17.19.1 COMPANY SNAPSHOT 374
  • 17.19.2 PRODUCT PORTFOLIO 374
  • 17.19.3 RECENT DEVELOPMENT 374
• 17.20 NUAIRE (A SUBSIDIARY OF GENUIT GROUP PLC) 375
  • 17.20.1 COMPANY SNAPSHOT 375
  • 17.20.2 REVENUE ANALYSIS 375
  • 17.20.3 PRODUCT PORTFOLIO 376
  • 17.20.4 RECENT DEVELOPMENTS 376
• 17.21 STERILINE (2021) 377
  • 17.21.1 COMPANY SNAPSHOT 377
  • 17.21.2 PRODUCT PORTFOLIO 377
  • 17.21.3 RECENT DEVELOPMENTS 377
• 17.22 SCHEMATIC ENGINEERING INDUSTRY 378
  • 17.22.1 COMPANY SNAPSHOT 378
  • 17.22.2 PRODUCT PORTFOLIO 378
  • 17.22.3 RECENT DEVELOPMENTS 378
• 17.23 SKAN AG 379
  • 17.23.1 COMPANY SNAPSHOT 379
  • 17.23.2 REVENUE ANALYSIS 379
  • 17.23.3 PRODUCT PORTFOLIO 380
  • 17.23.4 RECENT DEVELOPMENT 380
• 17.24 TEMA SINERGIE S.P.A 381
  • 17.24.1 COMPANY SNAPSHOT 381
  • 17.24.2 PRODUCT PORTFOLIO 381
  • 17.24.3 RECENT DEVELOPMENTS 382

18 QUESTIONNAIRE 384

19 RELATED REPORTS 388